Locations:
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Inflammatory protein eotaxin-1 may be a marker of future cognitive decline
Therapists and physicians collaborate to get medically stable patients moving
Designed for digitization, distance health, discovery and more
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Combining customized care, research capabilities and flexibility for the future
Using the EMR to identify subtle symptoms at triage
Leading investigators outline a new roadmap for clinical trials and observational research
The selective D1/D5 dopamine agonist provides symptom relief and improves daily function.
Integrating behavioral health expertise into the management of complex neurological disorders
5-year funding award supports cohort expansion and deep phenotyping of AD and related dementias
Advertisement
Advertisement
Search